



September 3, 2015

## **Agile Therapeutics to Participate at FBR Second Annual Healthcare Conference**

PRINCETON, N.J., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari, President and Chief Executive Officer will participate at the FBR Second Annual Healthcare Conference on Wednesday, September 9, 2015 in Boston, MA.

### **About Agile Therapeutics, Inc.**

Agile Therapeutics is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla<sup>®</sup>, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion<sup>®</sup>, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, please visit the company website at [www.agiletherapeutics.com](http://www.agiletherapeutics.com). The company may occasionally disseminate material, nonpublic information on the company website.

CONTACT: Mary Coleman

609.356.1921

Source: Agile Therapeutics

News Provided by Acquire Media